Dupixent Dip Dogs Sanofi Efforts To Deal With Diabetes Decline
Although sales of the closely-watched atopic dermatitis drug Dupixent disappointed in the first quarter, the French major sees the fall as an inventory-related blip and has high hopes that the therapy, as well as the contribution of recently acquired Bioverativ, will help fill the revenue hole left by Lantus.
You may also be interested in...
Swedish rare diseases specialist Sobi has reported strong financials and the acquisition of a rare disease candidate on the verge of US approval. Could partner Sanofi pop the question soon?
The French drugmaker and partner Lexicon now have a PDUFA date of March 22 next year for their dual inhibitor of SGLT-1 and SGLT-2 which is well placed to become the first oral antidiabetic to get the green light for use by adults with the type 1 form of the disease, in combination with insulin.
Sanofi will have €1.9bn to add to its war-chest when it concludes the sale of its European generics business.